> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Regulatory Pathway Needed for Dementia Vaccine Trials: Opinion
- URL: https://www.fdaweb.com/fda-regulatory-pathway-needed-for-dementia-vaccine-trials-opinion/
- Published: 2026-06-19T12:00:00.000Z
- Updated: 2026-09-14T13:41:32.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161338

An opinion article is calling on FDA acting commissioner **Kyle Diamantas** to establish a formal regulatory framework for evaluating vaccines as potential interventions to prevent dementia, arguing that the absence of clear guidance is hindering the launch of large-scale clinical trials.

In an [open letter](https://www.clinicaltrialvanguard.com/opinion/an-open-letter-to-acting-commissioner-diamantas-the-fda-needs-a-regulatory-pathway-for-vaccine-based-dementia-prevention-trials-now/?ref=fdaweb.com) published by *Clinical Trial Vanguard*, editor-in-chief **Moe Alsumidaie** cites a recent *Nature Medicine* paper that advocates for randomized trials of the live-attenuated shingles vaccine Zostavax as a potential strategy for reducing dementia risk.

The article points to growing epidemiological and mechanistic evidence linking reactivation of the varicella-zoster virus (VZV) to an increased risk of dementia, including research suggesting that VZV infection may contribute to cerebrovascular and neurodegenerative changes associated with Alzheimer's disease.

Alsumidaie argues that while both Zostavax and the recombinant shingles vaccine Shingrix are already licensed, FDA lacks a clear regulatory pathway for approving a vaccine-based dementia prevention indication. Current supplemental Biologics License Application (sBLA) processes were developed around infectious disease endpoints rather than long-term neurodegenerative outcomes, he contends.

The opinion piece notes that uncertainty around acceptable clinical endpoints, evidentiary standards and safety requirements could discourage sponsors from undertaking large, multi-year prevention studies that may require thousands of participants.

To address the issue, Alsumidaie urges CBER to convene a public workshop on vaccine-based dementia prevention trials, issue draft guidance outlining regulatory expectations for sponsors pursuing dementia prevention indications, and develop written recommendations on participant selection and safety monitoring for studies involving live-attenuated vaccines.

The article argues that regulatory clarity, rather than funding alone, may be the key obstacle to advancing research into whether existing vaccines could reduce the risk of dementia and Alzheimer's disease in aging populations.